Fludarabine
Inborn Error Of Immunity
Paul SzabolcsSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Inborn Error Of Immunity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulfanum medac GmbH | Phase 2 | B |
Treosulfan medac GmbH | Phase 2 | B |
Thiotepa Paul Szabolcs | Phase 2 | CCC |
Melphalan Paul Szabolcs | Phase 2 | CCC |
Clofarabine University of California, San Francisco | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative · Phase 2
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →